Shubham Pant, Ludmila K. Martin, Susan Geyer, Lai Wei, Katherine Van Loon, Nilli Sommovilla, Mark Zalupski, Renuka Iyer, David Fogelman, Andrew H. Ko and Tanios Bekaii-Saab Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab Cancer 120
Version of Record online: 13 MAR 2014 | DOI: 10.1002/cncr.28648
Patients with advanced pancreatic cancer with normal baseline serum albumin levels appear to derive benefit from bevacizumab. Future prospective investigations of bevacizumab in the treatment of advanced pancreatic cancer should consider selecting patients with normal baseline serum albumin to maximize potential benefit.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field